𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Vinblastine, ifosfamide, and gallium nitrate—an active new regimen in patients with advanced carcinoma of the urothelium : A Phase II trial of the Eastern Cooperative Oncology Group (E5892)

✍ Scribed by Robert Dreicer; Kathleen J. Propert; Bruce J. Roth; Lawrence H. Einhorn; Patrick J. Loehrer

Publisher
John Wiley and Sons
Year
1997
Tongue
English
Weight
71 KB
Volume
79
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

✦ Synopsis

vinblastine, ifosfamide, and gallium nitrate (VIG) as first-line chemotherapy in patients with locally advanced or metastatic carcinoma of the

📜 SIMILAR VOLUMES

An eastern cooperative oncology group ph
An eastern cooperative oncology group phase II trial of trimetrexate in the treatment of advanced urothelial carcinoma
✍ Robert S. Witte; Paul Elson; Janardan Khandakar; Donald L. Trump 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 359 KB 👁 2 views

## Background. Trimetrexate is an antifol that differs from methotrexate in ways that may be clinically important. Because methotrexate has activity in advanced bladder cancer, this trial was initiated.

Final report of a phase II evaluation of
Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck : An Eastern Cooperative Oncology Group trial (PA390)
✍ Arlene A. Forastiere; Darleen Shank; Donna Neuberg; Samuel G. Taylor IV; Ronald 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 68 KB 👁 1 views

The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute.

A randomized Phase II trial of echinomyc
A randomized Phase II trial of echinomycin, trimetrexate, and cisplatin plus etoposide in patients with metastatic nonsmall cell lung carcinoma : An Eastern Cooperative Oncology Group Study (E1587)
✍ Alex Y. Chang; KyungMann Kim; Hélène Boucher; Philip Bonomi; James A. Stewart; D 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 96 KB 👁 2 views

## Background: Patients with metastatic nonsmall cell lung carcinoma (nsclc) usually have a poor prognosis. a chemotherapy regimen containing cisplatin is commonly used for symptom palliation. echinomycin is a potent bifunctional intercalator of double-strand dna; trimetrexate is a new derivative o

A phase II study of 5-fluorouracil, leuc
A phase II study of 5-fluorouracil, leucovorin, and interferon-α in the treatment of patients with metastatic or recurrent gastric carcinoma : An Eastern Cooperative Oncology Group study (E5292)
✍ Gary R. Hudes; Stuart Lipsitz; Jean Grem; Mary Morrisey; Louis Weiner; John W. K 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 68 KB 👁 1 views

Chemotherapy has a limited impact on adenocarcinoma of the stomach. Although biochemical modulation of 5-fluorouracil (5-FU) by leucovorin (LV) and interferon-␣ (IFN-␣) has improved the outcomes of patients with metastatic colorectal carcinoma compared with 5-FU alone, this approach has not been ext

The combination of cisplatin, doxorubici
The combination of cisplatin, doxorubicin, and mitomycin (PAM) compared with the FAM regimen in treating advanced gastric carcinoma: A phase II randomized trial of the Italian oncology group for clinical research
✍ Vincenzo De Lisi; Giorgio Cocconi; Francesco Angelini; Francesco Cavicchi; Franc 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 482 KB 👁 2 views

## BACKGROUND. In a randomized Phase I1 study, the authors evaluated the activity and toxicity of the new cisplatin, doxorubicin, and mitomycin C (PAM) comhination, that includes cisplatin (P) instead of 5-fluorouracil as in the 5-fluorouracil, doxorubicin, and mitomycin C (FAM) Combination, in pat